Request Demo
Last update 24 May 2025
LHW-090
Last update 24 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms LHV-527, LHW 090, LHW090 |
Target |
Action inhibitors |
Mechanism enkephalinase inhibitors(Neprilysin inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with LHW-090NCT02678000
A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers
NCT02515331
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
NCT01846468
A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
100 Clinical Results associated with LHW-090
Login to view more data
100 Translational Medicine associated with LHW-090
Login to view more data
100 Patents (Medical) associated with LHW-090
Login to view more data
100 Deals associated with LHW-090
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Kidney Diseases | Phase 2 | United States | 10 Mar 2017 | |
| Chronic Kidney Diseases | Phase 2 | Germany | 10 Mar 2017 | |
| Resistant hypertension | Phase 2 | United States | 04 Nov 2015 | |
| Resistant hypertension | Phase 2 | Denmark | 04 Nov 2015 | |
| Resistant hypertension | Phase 2 | France | 04 Nov 2015 | |
| Resistant hypertension | Phase 2 | Germany | 04 Nov 2015 | |
| Resistant hypertension | Phase 2 | Netherlands | 04 Nov 2015 | |
| Resistant hypertension | Phase 2 | Switzerland | 04 Nov 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 64 | (LHW090 100 mg) | pzhrboxqmb = bivsikesol hfrawajqtf (ujdysdebkx, nchdhbkiav - fjzevapbse) View more | - | 05 Jul 2018 | ||
(LHW090 200 mg) | pzhrboxqmb = nxxfdjlbkb hfrawajqtf (ujdysdebkx, vmsccxmozm - gefgcrjpuw) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free